{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:08:17Z","timestamp":1789747697020,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jim.2026.114109","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:33:06Z","timestamp":1787700786000},"page":"114109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Influence of plate type on PBMC-based in vitro cytokine release assays for pre-clinical assessment of cytokine release syndrome"],"prefix":"10.1016","volume":"551","author":[{"given":"Geoffrey S.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Pribul-Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Kurach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimbai C.","family":"Edziwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B.","family":"Kernohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill K.","family":"Gower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitul","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyna","family":"Cortina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Euesden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis C.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jim.2026.114109_bb0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF01540642","article-title":"Method of production and control of a commercial tissue culture surface","volume":"16","author":"Barker","year":"1994","journal-title":"J. Tissue Cult. Methods"},{"key":"10.1016\/j.jim.2026.114109_bib62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jim.2003.07.013","article-title":"Differences in adsorption of serum proteins and production of IL-1ra by human monocytes incubated in different tissue culture microtiter plates","volume":"282","author":"Clinchy","year":"2003","journal-title":"J. Immunol. Methods"},{"issue":"23","key":"10.1016\/j.jim.2026.114109_bb0010","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.jim.2026.114109_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2009.10.013","article-title":"Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including tgn1412","volume":"352","author":"Findlay","year":"2010","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.jim.2026.114109_bb0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jim.2011.06.022","article-title":"Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy","volume":"371","author":"Findlay","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2026.114109_bb0025","series-title":"Guidance for Industry - Immunogenicity Assessment for Therapeutic Protein Products","year":"2014"},{"issue":"3","key":"10.1016\/j.jim.2026.114109_bb0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/0192623309332986","article-title":"The tegenero incident and the duff report conclusions: a series of unfortunate events or an avoidable event?","volume":"37","author":"Horvath","year":"2009","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jim.2026.114109_bb0035","article-title":"Using reference reagents to confirm robustness of cytokine release assays for the prediction of monoclonal antibody safety","volume":"199","author":"MacLeod","year":"2023","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jim.2026.114109_bb0040","series-title":"Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics - Guidance for Industry","year":"2023"},{"issue":"5","key":"10.1016\/j.jim.2026.114109_bb0045","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.4049\/jimmunol.179.5.3325","article-title":"\u201cCytokine storm\u201d in the phase i trial of monoclonal antibody tgn1412: better understanding the causes to improve preclinical testing of immunotherapeutics","volume":"179","author":"Stebbings","year":"2007","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.jim.2026.114109_bb0050","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-cd28 monoclonal antibody tgn1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2026.114109_bb0055","series-title":"Tgn1412 Investigational Medicinal Product Dossier","author":"TeGenero","year":"2005"},{"key":"10.1016\/j.jim.2026.114109_bib61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jim.2015.04.020","article-title":"Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials \u2014 Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm","volume":"424","author":"Vessillier","year":"2015","journal-title":"J. Immunol. Methods"},{"issue":"4","key":"10.1016\/j.jim.2026.114109_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytox.2020.100042","article-title":"Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - report of an international collaborative study","volume":"2","author":"Vessillier","year":"2020","journal-title":"Cytokine X"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175926000852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175926000852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:37:08Z","timestamp":1789745828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175926000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":14,"alternative-id":["S0022175926000852"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2026.114109","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of plate type on PBMC-based in vitro cytokine release assays for pre-clinical assessment of cytokine release syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2026.114109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 GSK. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114109"}}